Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial.
Am Heart J
; 235: 158-162, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1139418
ABSTRACT
The WiSE system is a novel, leadless endocardial system that can provide cardiac resynchronization therapy in patients who cannot be treated with a conventional epicardial left ventricular lead. Safety and efficacy were being evaluated in the pivotal, randomized, double-blind SOLVE-CRT Trial (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy.) The trial was initiated in 2018; however, patient enrollment was significantly impacted by the COVID-19 pandemic necessitating a change in design. This article describes the revised trial and the scientific rationale for the specific changes in the protocol.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Endocardium
/
Cardiac Resynchronization Therapy
/
Pandemics
/
COVID-19
/
Heart Failure
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Am Heart J
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS